A Phase II Trial of Everolimus and Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma (RCC)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 26 Jul 2017
At a glance
- Drugs Bevacizumab (Primary) ; Everolimus (Primary)
- Indications Renal cancer
- Focus Therapeutic Use
- Sponsors Novartis
- 15 Feb 2017 Planned number of patients changed from 54 to 55.
- 15 Feb 2017 Planned End Date changed from 1 Jul 2017 to 1 Jul 2018.
- 15 Feb 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Jul 2018.